Transmucosal amphiphile-protein conjugate vaccine
AssigneeMassachusetts Institute of Technology
InventorsDarrell J. Irvine, Brittany L. Hartwell
Life of this patent
Estimating the term…
Abstract
What is disclosed is a vaccine comprising an immunogen conjugated to an albumin-binding polymer-lipid tail, wherein the vaccine is suitable for transmucosal (e.g, intranasal) administration. Also disclosed is a method of using the vaccine to immunize a subject by transmucosal (e.g, intranasal) administration of an effective amount of the vaccine, alone or with an adjuvant.
Claims31
A vaccine comprising an amphiphilic conjugate, wherein the amphiphilic conjugate comprises an immunogen operably linked to an albumin-binding lipid, and wherein the vaccine is suitable for transmucosal administration to induce a humoral immune response.
(canceled)
-14. (canceled)
(canceled)
-23. (canceled)
(canceled)
-28. (canceled)
-34. (canceled)
(canceled)
-42. (canceled)
Dependencies are inferred from the claim text.